Literature DB >> 20937266

UPLC MS/MS method for quantification of mycophenolic acid and metabolites in human plasma: Application to pharmacokinetic study.

Xavier Delavenne1, Ludivine Juthier, Bertrand Pons, Christophe Mariat, Thierry Basset.   

Abstract

BACKGROUND: We described the development and full validation of a rapid, high throughput sensible and accurate UPLC method using tandem mass spectrometry detection for mycophenolate acid (MPA) and its metabolites, MPA glucuronide (MPAG) and acyl MPA glucuronide (AcMPAG) concentration determination with MPA-D3 as internal standard in human plasma.
METHODS: Plasma pretreatment involved a one-step protein precipitation with acetonitrile. The separation was performed by reverse-phase chromatography on a Waters BEH HSST3 100 mm*2.1 mm*1.8 μm column. The multiple reaction monitoring transitions used for quantification were m/z 321.04→303.02 for MPA, 524.09→303.02 for AcMPAG and MPAG and 324.03→306.04 for MPA-D3 in the electrospray positive ionization mode.
RESULTS: The method was linear over the concentration range of 0.1-20mg/L for MPA and AcMPAG and 1-200mg/L for MPAG respectively. The intra- and inter-day precision values were below 14% and accuracy was from 94.0 to 103.3% at all quality control levels. The lower LOQ was 0.1 mg/L for MPA and AcMPAG, 1 mg/L for MPAG.
CONCLUSION: Sample analysis time was reduced to 7 min including sample preparation. The present method was successfully applied to a pharmacokinetic study following oral administration of enterocoated sodium mycophenolate in de novo renal transplantation.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20937266     DOI: 10.1016/j.cca.2010.09.041

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  A high-throughput U-HPLC-MS/MS assay for the quantification of mycophenolic acid and its major metabolites mycophenolic acid glucuronide and mycophenolic acid acyl-glucuronide in human plasma and urine.

Authors:  Jacek Klepacki; Jelena Klawitter; Jamie Bendrick-Peart; Bjorn Schniedewind; Svenja Heischmann; Touraj Shokati; Uwe Christians; Jost Klawitter
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-08-02       Impact factor: 3.205

2.  Investigation of the Association Between Total and Free Plasma and Saliva Mycophenolic Acid Concentrations Following Administration of Enteric-Coated Mycophenolate Sodium in Adult Kidney Transplant Recipients.

Authors:  Emily Brooks; Susan E Tett; Nicole M Isbel; Brett McWhinney; Christine E Staatz
Journal:  Clin Drug Investig       Date:  2019-12       Impact factor: 2.859

3.  Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis.

Authors:  Azrin N Abd Rahman; Susan E Tett; Halim A Abdul Gafor; Brett C McWhinney; Christine E Staatz
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-12       Impact factor: 2.441

4.  Development and application of monoclonal antibodies against the mycotoxin mycophenolic acid.

Authors:  Richard Dietrich; Erwin Märtlbauer
Journal:  Mycotoxin Res       Date:  2015-09-17       Impact factor: 3.833

5.  Determination of mycophenolic acid in human plasma by ultra performance liquid chromatography tandem mass spectrometry.

Authors:  Vivek Upadhyay; Vikas Trivedi; Gaurang Shah; Manish Yadav; Pranav S Shrivastav
Journal:  J Pharm Anal       Date:  2013-06-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.